Literature DB >> 19584819

Strategies to modulate immune responses: a new frontier for gene therapy.

Valder R Arruda1, Patricia Favaro, Jonathan D Finn.   

Abstract

The success of gene therapy strategies to cure disease relies on the control of unwanted immune responses to transgene products, genetically modified cells and/or to the vector. Effective treatment of an established immune response is much harder to achieve than prevention of a response before it has had a chance to develop. However, preventive strategies are not always effective in avoiding immune responses, thus the use of drugs to induce immunosuppression (IS) is required. The growing discovery of novel drugs provides a conceptual shift from using generalized, moderately intensive immunosuppressive regimens towards a refined approach to attain the optimal balance of naive cells, effector cells, memory cells, and regulatory cells, harnessing the natural tolerance mechanisms of the body. We review several strategies based on transient IS coupled with gene therapy for sustained immune tolerance induction to the therapeutic transgene.

Mesh:

Year:  2009        PMID: 19584819      PMCID: PMC2835266          DOI: 10.1038/mt.2009.150

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  111 in total

Review 1.  Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Authors:  Joan Bladé; M Teresa Cibeira; Laura Rosiñol
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

2.  Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models.

Authors:  V R Arruda
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

3.  Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.

Authors:  Lingfei Xu; Timothy C Nichols; Rita Sarkar; Stephanie McCorquodale; Dwight A Bellinger; Katherine P Ponder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

4.  Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice.

Authors:  Carol H Miao; Peiqing Ye; Arthur R Thompson; David J Rawlings; Hans D Ochs
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

5.  Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.

Authors:  Colin J D Ross; Jaap Twisk; Andrew C Bakker; Fudan Miao; Dennis Verbart; Jaap Rip; Tamara Godbey; Paul Dijkhuizen; Wim T J M C Hermens; John J P Kastelein; Jan Albert Kuivenhoven; Janneke M Meulenberg; Michael R Hayden
Journal:  Hum Gene Ther       Date:  2006-05       Impact factor: 5.695

6.  Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.

Authors:  Rita Sarkar; Melinda Mucci; Sankar Addya; Renee Tetreault; Dwight A Bellinger; Timothy C Nichols; Haig H Kazazian
Journal:  Hum Gene Ther       Date:  2006-04       Impact factor: 5.695

7.  Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.

Authors:  Eric Dobrzynski; Julie C Fitzgerald; Ou Cao; Federico Mingozzi; Lixin Wang; Roland W Herzog
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-10       Impact factor: 11.205

8.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.

Authors:  Valder R Arruda; Hansell H Stedman; Timothy C Nichols; Mark E Haskins; Matthew Nicholson; Roland W Herzog; Linda B Couto; Katherine A High
Journal:  Blood       Date:  2004-10-12       Impact factor: 22.113

9.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

10.  Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation.

Authors:  L Denby; S A Nicklin; A H Baker
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

View more
  31 in total

1.  Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

Authors:  Valder R Arruda; Hansell H Stedman; Virginia Haurigot; George Buchlis; Stefano Baila; Patricia Favaro; Yifeng Chen; Helen G Franck; Shangzhen Zhou; J Fraser Wright; Linda B Couto; Haiyan Jiang; Glenn F Pierce; Dwight A Bellinger; Federico Mingozzi; Timothy C Nichols; Katherine A High
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

2.  An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.

Authors:  Joseph E Doherty; Lauren E Woodard; Adham S Bear; Aaron E Foster; Matthew H Wilson
Journal:  FASEB J       Date:  2013-06-10       Impact factor: 5.191

Review 3.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

4.  Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.

Authors:  Dheeraj Verma; Babak Moghimi; Paul A LoDuca; Harminder D Singh; Brad E Hoffman; Roland W Herzog; Henry Daniell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

5.  In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.

Authors:  Andrea Annoni; Brian D Brown; Alessio Cantore; Lucia Sergi Sergi; Luigi Naldini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

Review 6.  Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

Authors:  Perry B Hackett; Elena L Aronovich; David Hunter; Myra Urness; Jason B Bell; Steven J Kass; Laurence J N Cooper; Scott McIvor
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

Review 7.  The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

Authors:  Elena L Aronovich; R Scott McIvor; Perry B Hackett
Journal:  Hum Mol Genet       Date:  2011-04-01       Impact factor: 6.150

Review 8.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

9.  The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.

Authors:  Z S Guo; V Parimi; M E O'Malley; P Thirunavukarasu; M Sathaiah; F Austin; D L Bartlett
Journal:  Gene Ther       Date:  2010-08-12       Impact factor: 5.250

10.  Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.

Authors:  Joshua I Siner; Nicholas P Iacobelli; Denise E Sabatino; Lacramiora Ivanciu; Shangzhen Zhou; Mortimer Poncz; Rodney M Camire; Valder R Arruda
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.